Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MA022-2037
- Development stage
- Preclinical
- Lead developer
- MyriO Tx
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MA022-2037 is a half-life extended bispecific T-cell engager (BiTE) developed by Myrio Therapeutics. It is specifically designed to target solid tumors harboring the KRAS G12V mutation in patients who are HLA-A*11:01-positive. The therapeutic utilizes fully human single-chain variable fragments (scFv) that selectively recognize a 10-mer peptide derived from the KRAS G12V neoantigen when presented by the HLA-A*11:01 complex, while avoiding cross-reactivity with the corresponding wild-type KRAS peptide. By simultaneously binding the tumor-specific peptide-HLA complex and the CD3 receptor on T cells, MA022-2037 redirects T-cell cytotoxicity to eliminate KRAS G12V-expressing cancer cells. It is currently undergoing IND-enabling studies for the treatment of lung, pancreatic, and colon cancers.
- Other names
- KRAS G12V T cell engager (A*11)KRAS (G12V) T Cell Engager (A*11)KRAS G12V T-cell engager (A*11)
02
Targets
KRAS G12V/HLA-A*11:01 (KRAS G12V Mutant Peptide-HLA-A*11:01 Complex)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on MA022-2037.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MA022-2037.